OBJECTIVES: We aimed to evaluate cardiovascular (CV) risk in patients with idiopathic inflammatory myopathies (IIM) compared with healthy controls (HC) and to assess its association with disease-specific features. METHODS: Ninety IIM patients and 180 age-/sex-matched HC were included. Subjects with a history of CV disease (angina pectoris, myocardial infarction and cerebrovascular/peripheral arterial vascular events) were excluded. All participants were prospectively recruited and underwent examinations of carotid intima-media thickness (CIMT), pulse wave velocity (PWV), ankle-brachial index (ABI), and body composition. The risk of fatal CV events was evaluated by the Systematic COronary Risk Evaluation (SCORE) and its modifications. RESULTS: Compared with HC, IIM patients had a significantly higher prevalence of traditional CV risk factors, carotid artery disease (CARD), abnormal ABI and PWV. After propensity score matching (using traditional CV risk factors), the prevalence of CARD and pathological PWV remained significantly higher in IIM than HC. No significant difference in SCORE was observed. The most unfavourable CV risk profile was observed in patients with necrotizing myopathy, especially in statin-induced anti-HMGCR+ patients. The calculated CV risk scores by SCORE, SCORE2 and SCORE multiplied by the coefficient 1.5 (mSCORE) were reclassified according to CIMT and the presence of carotid plaques. SCORE was demonstrated to be most inaccurate in predicting CV risk in IIM. Age, disease activity, lipid profile, body composition parameters and blood pressure were the most significant predictors of CV risk in IIM patients. CONCLUSION: Significantly higher prevalence of traditional risk factors and subclinical atherosclerosis was observed in IIM patients compared with HC.

3rd Department of Internal Medicine General University Hospital and 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Biomedical Technology Faculty of Biomedical Engineering Czech Technical University Prague Kladno Czech Republic

Department of Human Movement Laboratory Faculty of Physical Education and Sport Charles University Prague Czech Republic

Department of Physiotherapy Faculty of Physical Education and Sport Charles University Prague Czech Republic

Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic

Institute of Rheumatology Prague Czech Republic

Zobrazit více v PubMed

Mc Namara K, Alzubaidi H, Jackson JK.. Cardiovascular disease as a leading cause of death: how are pharmacists getting involved? Integr Pharm Res Pract 2019;8:1–11. PubMed PMC

Frostegard J. Immunity, atherosclerosis and cardiovascular disease. BMC Med 2013;11:117. PubMed PMC

Sanjadi M, Rezvanie Sichanie Z, Totonchi H. et al. Atherosclerosis and autoimmunity: a growing relationship. Int J Rheum Dis 2018;21:908–21. PubMed

Castaneda S, Martin-Martinez MA, Gonzalez-Juanatey C. et al.; CARMA Project Collaborative Group. Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: baseline data of the CARMA Project. Semin Arthritis Rheum 2015;44:618–26. PubMed

Bohan A, Peter JB.. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344–7. PubMed

Bohan A, Peter JB.. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403–7. PubMed

Lundberg IE, de Visser M, Werth VP.. Classification of myositis. Nat Rev Rheumatol 2018;14:269–78. PubMed

Rose MR; ENMC IBM Working Group. 188th ENMC International Workshop: Inclusion Body Myositis, 2–4 December 2011, Naarden, The Netherlands. Neuromuscul Disord 2013;23:1044–55. PubMed

Hoogendijk JE, Amato AA, Lecky BR. et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004;14:337–45. PubMed

Ungprasert P, Suksaranjit P, Spanuchart I, Leeaphorn N, Permpalung N.. Risk of coronary artery disease in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis of observational studies. Semin Arthritis Rheum 2014;44:63–7. PubMed

Dobloug GC, Svensson J, Lundberg IE, Holmqvist M.. Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study. Ann Rheum Dis 2018;77:40–7. PubMed

Rai SK, Choi HK, Sayre EC, Avina-Zubieta JA.. Risk of myocardial infarction and ischaemic stroke in adults with polymyositis and dermatomyositis: a general population-based study. Rheumatology (Oxford) 2016;55:461–9. PubMed

Schwartz T, Diederichsen LP, Lundberg IE, Sjaastad I, Sanner H.. Cardiac involvement in adult and juvenile idiopathic inflammatory myopathies. RMD Open 2016;2:e000291. PubMed PMC

Catapano AL, Reiner Z, De Backer G. et al.; The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias . Atherosclerosis 2011;217:3–46. PubMed

Anderson KM, Odell PM, Wilson PW, Kannel WB.. Cardiovascular disease risk profiles. Am Heart J 1991;121:293–8. PubMed

Kerekes G, Soltesz P, Nurmohamed MT. et al. Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nat Rev Rheumatol 2012;8:224–34. PubMed

Conroy RM, Pyorala K, Fitzgerald AP. et al.; SCORE Project Group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987–1003. PubMed

SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 2021;42:2439–54. PubMed PMC

Agca R, Heslinga SC, Rollefstad S. et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017;76:17–28. PubMed

Drosos GC, Vedder D, Houben E. et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis 2022;81:768–79. PubMed

Nambi V, Chambless L, Folsom AR. et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol 2010;55:1600–7. PubMed PMC

Ankle Brachial Index Collaboration, Fowkes FG, Murray GD. et al.Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008;300:197–208. PubMed PMC

Laurent S, Cockcroft J, Van Bortel L. et al.; European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27:2588–605. PubMed

Lundberg IE, Tjarnlund A, Bottai M. et al.; International Myositis Classification Criteria Project Consortium, the Euromyositis Register, and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol 2017;69:2271–82. PubMed PMC

Špiritović M, Heřmánková B, Oreská S. et al. The effect of a 24-week training focused on activities of daily living, muscle strengthening, and stability in idiopathic inflammatory myopathies: a monocentric controlled study with follow-up. Arthritis Res Ther 2021;23:173. PubMed PMC

Oreska S, Storkanova H, Kudlicka J. et al. Cardiovascular risk in myositis patients compared to the general population: preliminary data from a single-center cross-sectional study. Front Med (Lausanne) 2022;9:861419. PubMed PMC

Williams B, Mancia G, Spiering W. et al.; Authors/Task Force Members. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018;36:1953–2041. PubMed

Johri AM, Nambi V, Naqvi TZ. et al. Recommendations for the assessment of carotid arterial plaque by ultrasound for the characterization of atherosclerosis and evaluation of cardiovascular risk: from the American Society of Echocardiography. J Am Soc Echocardiogr 2020;33:917–33. PubMed

Petrak O, Rosa J, Holaj R. et al. Blood pressure profile, catecholamine phenotype, and target organ damage in pheochromocytoma/paraganglioma. J Clin Endocrinol Metab 2019;104:5170–80. PubMed

Rooke TW, Hirsch AT, Misra S. et al.; Society for Vascular Surgery. ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2011;58:2020–45. PubMed PMC

Xiong A, Hu Z, Zhou S. et al. Cardiovascular events in adult polymyositis and dermatomyositis: a meta-analysis of observational studies. Rheumatology (Oxford) 2022;61:2728–39. PubMed

Visseren FLJ, Mach F, Smulders YM. et al.; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42:3227–337. PubMed

Triantafyllias K, Cavagna L, Klonowski A. et al. Possible misclassification of cardiovascular risk by SCORE in antisynthetase syndrome: results of the pilot multicenter study RI.CAR.D.A. Rheumatology (Oxford) 2021;60:1300–12. PubMed

Vincze M, Der H, Kerekes G. et al. Decreased flow-mediated dilatation with increased arterial stiffness and thickness as early signs of atherosclerosis in polymyositis and dermatomyositis patients. Clin Rheumatol 2014;33:1635–41. PubMed

Barsotti S, Saponaro C, Gaggini M. et al. Cardiometabolic risk and subclinical vascular damage assessment in idiopathic inflammatory myopathies: a challenge for the clinician. Clin Exp Rheumatol 2019;37:1036–43. PubMed

Limaye VS, Lester S, Blumbergs P, Roberts-Thomson PJ.. Idiopathic inflammatory myositis is associated with a high incidence of hypertension and diabetes mellitus. Int J Rheum Dis 2010;13:132–7. PubMed

Silva MG, Borba EF, Mello SB, Shinjo SK.. Serum adipocytokine profile and metabolic syndrome in young adult female dermatomyositis patients. Clinics (Sao Paulo) 2016;71:709–14. PubMed PMC

de Souza FH, Shinjo SK.. The high prevalence of metabolic syndrome in polymyositis. Clin Exp Rheumatol 2014;32:82–7. PubMed

Diederichsen LP, Diederichsen AC, Simonsen JA. et al. Traditional cardiovascular risk factors and coronary artery calcification in adults with polymyositis and dermatomyositis: a Danish multicenter study. Arthritis Care Res (Hoboken) 2015;67:848–54. PubMed

de Moraes MT, de Souza FH, de Barros TB, Shinjo SK.. Analysis of metabolic syndrome in adult dermatomyositis with a focus on cardiovascular disease. Arthritis Care Res (Hoboken) 2013;65:793–9. PubMed

Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008;121:S21–31. PubMed

Péter A, Balogh Á, Csanádi Z, Dankó K, Griger Z.. Subclinical systolic and diastolic myocardial dysfunction in polyphasic polymyositis/dermatomyositis: a 2-year longitudinal study. Arthritis Res Ther 2022;24:219. PubMed PMC

Laporte A, Mariampillai K, Allenbach Y. et al. Idiopathic inflammatory myopathies: CT characteristics of interstitial lung disease and their association(s) with myositis-specific autoantibodies. Eur Radiol 2022;32:3480–9. PubMed

Xu F, Lv S, Chen Y. et al. Macrophage inflammatory protein-1beta and fibrinogen are synergistic predictive markers of prognosis of intermediate coronary artery lesions. Cardiology 2012;121:12–9. PubMed

Altara R, Manca M, Hessel MH. et al. CXCL10 is a circulating inflammatory marker in patients with advanced heart failure: a pilot study. J Cardiovasc Transl Res 2016;9:302–14. PubMed

Wu PH, Glerup RI, Svensson MHS. et al. Novel biomarkers detected by proteomics predict death and cardiovascular events in hemodialysis patients. Biomedicines 2022;10:740. PubMed PMC

Gu L, Liu H, Liu X. et al. The relationship between interleukin-4 levels and cardiovascular events in patients with chronic kidney disease. Risk Manag Healthc Policy 2020;13:2371–7. PubMed PMC

Ridker PM, Everett BM, Pradhan A. et al.; CIRT Investigators. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019;380:752–62. PubMed PMC